Semliki Forest Virus (SFV) Self-Amplifying RNA Delivered to J774A.1 Macrophage Lineage by Its Association with a Purified Recombinant SFV Capsid Protein DOI Open Access

Roselane P. Gomes,

Flávia Ferreira Barbosa,

Marcelo A. S. Toledo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7859 - 7859

Published: July 18, 2024

The Semliki Forest virus capsid protein (C) is an RNA binding which exhibits both specific and unspecific affinities to single-strand nucleic acids. putative use of the self-amplifying RNAs (saRNAs) alphaviruses for biotechnological purpose one main studied strategies concerning RNA-based therapies or immunization. In this work, a recombinant C from SFV was expressed purified bacteria used associate in vitro with saRNA derived SFV. Results showed that form can even after high temperature treatment. associated modified coding green fluorescent (GFP) delivered murine macrophage cells GFP, showing functional being protein.

Language: Английский

Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions DOI Creative Commons
Lei‐Ming Cao, Yifu Yu, Zi‐Zhan Li

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 2, 2024

Abstract Research into mRNA vaccines is advancing rapidly, with proven efficacy against coronavirus disease 2019 and promising therapeutic potential a variety of solid tumors. Adjuvants, critical components vaccines, significantly enhance vaccine effectiveness are integral to numerous formulations. However, the development selection adjuvant platforms still in their nascent stages, mechanisms many adjuvants remain poorly understood. Additionally, immunostimulatory capabilities certain novel drug delivery systems (DDS) challenge traditional definition adjuvants, suggesting that revision this concept necessary. This review offers comprehensive exploration applications self-adjuvant DDS. It thoroughly addresses existing issues mentioned above details three main challenges immune-related adverse event, unclear mechanisms, unsatisfactory outcomes old age group design practical application cancer adjuvants. Ultimately, proposes optimization strategies which consists exploring adjuvant, optimizing DDS, improving route administration improve

Language: Английский

Citations

6
mRNA-based vaccines – global approach, challenges, and could be a promising wayout for future pandemics DOI
Shivani Makhijani,

Gehan M. Elossaily,

Satish Rojekar

et al.

Pharmaceutical Development and Technology, Journal Year: 2024, Volume and Issue: 29(6), P. 559 - 565

Published: May 30, 2024

mRNA-based vaccines are assured to significantly boost biopharmaceuticals since outbreak of coronavirus disease- 2019. Respiratory infections, such as influenza, SARS, MERS, COVID-19, and respiratory syncytial virus, often have high transmission rates due their airborne spread. infections can lead severe illness death. These outbreaks cause substantial economic social disruption, seen with the COVID-19 pandemic. In our interconnected world, diseases spread rapidly across borders. (e.g., mRNA-1283) reduce by creating immunity in population, thus lowering incidence these diseases. Vaccines crucial for global health security, helping prevent local from becoming pandemics. Nevertheless, various concerns remain intracellular delivery, susceptibility degradation catalytic hydrolysis, instability several physiological conditions. Therefore, an hour needed address challenges opportunities attaining high-quality stable novel drug delivery systems. The authors contributed extensive review clinical development, progress stability mitigate market needs. addition, discuss advances growth date; which dominate scope therapeutic implementation. Finally, recent trials, adjuvant benefits, prospects discussed.

Language: Английский

Citations

5
Eastern equine encephalitis virus: Pathogenesis, immune response, and clinical manifestations DOI Creative Commons
Bhupesh Parashar, Rishabha Malviya, Sathvik Belagodu Sridhar

et al.

Infectious Medicine, Journal Year: 2025, Volume and Issue: 4(1), P. 100167 - 100167

Published: Jan. 18, 2025

Language: Английский

Citations

0
Peptides: Potential Delivery Systems for mRNA DOI Creative Commons

Huiting Liang,

Yun Xing, Kai Wang

et al.

RSC Chemical Biology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Peptide-based delivery systems advance mRNA therapies for protein replacement, gene editing, and vaccine development.

Language: Английский

Citations

0
Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations DOI
Yadollah Omidi, Mohammad M. Pourseif, Rais A. Ansari

et al.

Nanomedicine, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 27

Published: Nov. 13, 2024

The rapid evolution of mRNA vaccines, highlighted by Pfizer-BioNTech and Moderna's COVID-19 has transformed vaccine development therapeutic approaches. Self-amplifying (saRNA) a groundbreaking advancement in RNA-based offer promising possibilities for disease prevention treatment, including potential applications cancer neurodegenerative diseases. This review explores the complex design these innovative with focus on their nanoscale formulations that utilize nanotechnology to improve delivery effectiveness. It articulates fundamental principles saRNA mechanisms action, role synthetic eliciting immune responses. further elaborates various systems (e.g., lipid nanoparticles, polymeric nanoparticles other nanocarriers), emphasizing advantages enhancing stability cellular uptake. addresses advanced techniques such as microfluidics discusses challenges formulating vaccines. By incorporating latest technologies current research, this provides thorough overview recent nanovaccines advancements, highlighting revolutionize technology broaden clinical applications.

Language: Английский

Citations

2
Transfection of hypoxia-inducible factor-1α mRNA upregulates the expression of genes encoding angiogenic growth factors DOI Creative Commons
Jakub Włodarczyk, Albert Leng, Sanaz Nourmohammadi Abadchi

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: March 20, 2024

Abstract Hypoxia-Inducible Factor-1α (HIF-1α) has presented a new direction for ischemic preconditioning of surgical flaps to promote their survival. In previous study, we demonstrated the effectiveness HIF-1a DNA plasmids in this application. avoid complications associated with plasmid use, sought express HIF-1α through mRNA transfection and determine its biological activity by measuring upregulation downstream angiogenic genes. We transfected six different mRNAs–one predominant, three variant, two novel mutant isoforms–into primary human dermal fibroblasts using Lipofectamine, assessed levels RT-qPCR. At all time points examined after (3, 6, 10 h), transcript were significantly higher cells relative control (all p < 0.05, unpaired Student’s T-test). Importantly, expression transcription response genes (VEGF, ANG-1, PGF, FLT1, EDN1) was isoforms than at and/or ten hours post-transfection. All successfully into fibroblast cells, resulting rapid five targets tested. These findings support potential use protecting flaps.

Language: Английский

Citations

1
Rational Design of Lipid-Based Vectors for Advanced Therapeutic Vaccines DOI Creative Commons
Yufei Ma, Yiang Chen, Zilu Li

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 603 - 603

Published: May 31, 2024

Recent advancements in vaccine delivery systems have seen the utilization of various materials, including lipids, polymers, peptides, metals, and inorganic substances, for constructing non-viral vectors. Among these, lipid-based nanoparticles, composed natural, synthetic, or physiological lipid/phospholipid offer significant advantages such as biocompatibility, biodegradability, safety, making them ideal delivery. These vectors can protect encapsulated antigens and/or mRNA from degradation, precisely tune chemical physical properties to mimic viruses, facilitate targeted specific immune cells, enable efficient endosomal escape robust activation. Notably, vaccines, exemplified by those developed BioNTech/Pfizer Moderna against COVID-19, gained approval human use. This review highlights rational design strategies delivery, emphasizing lymphoid organ targeting effective escape. It also discusses importance formulation structure–activity relationships, along with reviewing components potential applications Additionally, it addresses current challenges future prospects translating therapies cancer infectious diseases into clinical practice.

Language: Английский

Citations

0
Semliki Forest Virus (SFV) Self-Amplifying RNA Delivered to J774A.1 Macrophage Lineage by Its Association with a Purified Recombinant SFV Capsid Protein DOI Open Access

Roselane P. Gomes,

Flávia Ferreira Barbosa,

Marcelo A. S. Toledo

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7859 - 7859

Published: July 18, 2024

The Semliki Forest virus capsid protein (C) is an RNA binding which exhibits both specific and unspecific affinities to single-strand nucleic acids. putative use of the self-amplifying RNAs (saRNAs) alphaviruses for biotechnological purpose one main studied strategies concerning RNA-based therapies or immunization. In this work, a recombinant C from SFV was expressed purified bacteria used associate in vitro with saRNA derived SFV. Results showed that form can even after high temperature treatment. associated modified coding green fluorescent (GFP) delivered murine macrophage cells GFP, showing functional being protein.

Language: Английский

Citations

0